Radioiodtherapie bei benignen Schilddrüsenerkrankungen (Version 5)^*

Schlüsselwörter

Leitlinie - Radioiodtherapie - Schilddrüsenüberfunktion - Morbus Basedow - Autonomie - Struma

Keywords

Guideline - radioiodine therapy - hyperthyroidism - thyrotoxicosis - Graves’ disease - toxic goiter

 

• Literatur

• 1 Bachmann J, Kobe C, Bor S. et al. Radioiodine therapy for thyroid volume reduction of large goitres. Nucl Med Commun 2009; 30: 466-471.
• 2 Bahn RS, Burch HB, Cooper DS. et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21: 593-641.
• 3 Bartalena L, Marcocci C, Bogazzi F. et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998; 338: 73-78.
• 4 Bartalena L, Baldeschi L, Dickinson A. et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158: 273-285.
• 5 Bonnema SJ, Bennedbaek FN, Veje A. et al. Propylthiouracil before I-131 therapy of hyperthyroid diseases; effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 2004; 89: 4439-4444
• 6 Bonnema SJ, Nielsen VE, Boel-Jørgensen H. et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007; 92: 3424-3434.
• 7 Cappelen T, Unhjem JF, Amundsen AL. et al. Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131. Eur J Nucl Med 2006; 33: 81-86.
• 8 Ceccarelli C, Bencivelli W, Vitti P. et al. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol (Oxf) 2005; 62: 331-335.
• 9 Chao M, Jiawei X, Guoming W. et al. Radioiodine treatment for pediatric hyperthyroid Graves’ disease. Eur J Pediatr 2009; 168: 1165-1169.
• 10 Chen DY, Jing J, Schneider PF, Chen TH. Comparison of the long-term efficacy of low-dose ¹³¹I versus antithyroid drugs in the treatment of hyperthyroidism. Nucl Med Commun 2009; 30: 160-168.
• 11 Chen DY, Schneider PF, Zhang XS. et al. Striving for euthyroidism in radioiodine therapy of Graves’ disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid 2011; 21: 647-654.
• 12 Chen DY, Schneider PF, Zhang XS. et al. Changes in Graves’ ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves’ disease from 2 prospective, randomized, open-label, blinded end point studies. Exp Clin Endocrinol Diabetes 2014; 122: 1-6.
• 13 Cooper DS, Doherty GM, Haugen BR. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
• 14 Dederichs B, Dietlein M, Jenniches-Kloth B. et al. Radioiodine therapy of Graves’ hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy?. Exp Clin Endocrinol Diabetes 2006; 115: 366-370.
• 15 Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie. Operative Therapie benigner Schilddrüsenerkrankungen. AWMF-Leitlinien-Register Nr. 003/002, letzte Aktualisierung. 2010 www.awmf.de/leitlinien/detail/II/003-002.html
• 16 Dietlein M, Dederichs B, Kobe C. et al. Therapy for non-toxic multinodular goiter: radioiodine therapy as attractive alternative to surgery. Nuklearmedizin 2006; 45: 21-34.
• 17 Dietlein M, Eschner W, Lassmann M. et al. DGN-Handlungsempfehlung (S1-Leitlinie): Radioiodtest (Version 4). Stand 10/2014 - AWMF-Registernummer: 031-012
• 18 Dietlein M, Eschner W, Lassmann H. et al. DGN-Handlungsempfehlung (S1-Leitlinie): Schilddrüsenszintigraphie (Version 4). Stand 10/2014 - AWMF-Registernummer: 031-011
• 19 Dralle H, Sekulla C. Morbidität nach subtotaler und totaler Thyreoidektomie beim Morbus Basedow: Entscheidungsgrundlage für Operationsindikation und Resektionsausmaß. Z Ärztl Fortbild Qual Gesundh 2004; 98 (Suppl V) 45-53.
• 20 Dunkelmann S, Endlicher D, Prillwitz A. et al. Ergebnisse der TcTUs-optimierten Radioiodtherapie bei multifokaler und disseminierter Autonomie. Nuklearmedizin 1999; 38: 131-139.
• 21 Dunkelmann S, Wolf R, Koch A. et al. Incidence of radiation-induced Graves’ disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med 2004; 31: 1428-1434.
• 22 Dunkelmann S, Neumann V, Staub U. et al. Ergebnisse einer risikoadaptierten und funktionsorientierten Radioiodtherapie bei Morbus Basedow. Nuklearmedizin 2005; 44: 238-242.
• 23 Dunkelmann S, Kuenster H, Nabavi E. et al. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves’ disease. Eur J Nucl Med Mol Imaging 2007; 34: 228-236.
• 24 Eckstein AE, Plicht M, Lex H. et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91: 3464-3470.
• 25 Fast S, Nielsen VE, Grupe P. et al. Optimizing ¹³¹I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med 2009; 50: 732-737.
• 26 Fast S, Hegedüs L, Pacini F. et al. Long-term efficacy of modified release recombinant human thyrotropin augmented radioiodine therapy for begnin multinodular goiter: results from a multicenter, international, randomized, placebo-controlled, dose-selection study. Thyroid 2014; 24: 727-735.
• 27 Holm LE, Lundell G, Israelsson A, Dahlqvist I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med 1982; 23: 103-107.
• 28 International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. Ann ICRP 2004; 34: 1-79 Erratum in: Ann ICRP 2004; 34: 281. Ann ICRP 2006; 36: 77.
• 29 Jensen BE, Bonnema SJ, Hegedues L. Glucocorticoids do not influence the effect of radioiodine therapy in Graves’ disease. Eur J Endocrinol 2005; 153: 15-21.
• 30 Kahaly GJ, Bartalena L, Hegedüs L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid 2008; 21: 585-591.
• 31 Kahraman D, Keller C, Schneider C. et al. Development of hypothyroidism in long-term follow-up in patients with toxic goiter after radioiodine therapy. Clin Endocrinol 2012; 76: 297-303.
• 32 Kobe C, Eschner W, Sudbrock F. et al. Graves’ disease and radioidine therapy: Is success of ablation dependent on the achieved dose above 200 Gy?. Nuklearmedizin 2008; 47: 13-17.
• 33 Kobe C, Weber I, Eschner W. et al. Graves’ disease and radioiodine therapy: is success of ablation dependent on the choice of thyreostatic medication?. Nuklearmedizin 2008; 47: 153-166.
• 34 Kobe C, Eschner W, Wild M. et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of ¹³¹I?. Nucl Med Commun 2010; 31: 201-205.
• 35 Kubota S, Ohye H, Yano G. et al. Two-day thioamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves’ disease. Endocrine J 2006; 53: 603-607.
• 36 Lai A, Sassi L, Compri E. et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010; 95: 1333-1337.
• 37 Lantz M, Planck T, Asman P, Hallengren B. Increased TRAb and/or low anti-TPO titers at diagnosis of Graves’ disease are associated with an increased risk of developing ophthalmopathy after onset. Exp Clin Endocrinol Diabetes 2014; 122: 113-117.
• 38 Lee YY, Tam KW, Lin YM. et al. Recombinant human thyrotropin before iodine-131 therapy in patients with nodular goiter: a meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf) 2015; 83: 702-710.
• 39 Ma C, Kuang A, Xie J, Liu GJ. Radioiodine for pediatric Graves’ disease. John Wiley & Sons, Ltd, 2009. Cochrane Database of Systematic Reviews. 2008 Issue 3. Art. No.: CD006294.
• 40 Nielsen VE, Bonnema SJ, Boel-Jorgensen H. et al. Stimulation with 0.3 mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign non-toxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006; 166: 1476-1482.
• 41 Nieuwlaat WA, Huysmans DA, van den Bosch HC. et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003; 88: 3121-3129.
• 42 Nimmons GL, Funk GF, Graham MM, Pagedar NA. Urinary iodine excretion after contrast computed tomography scan: implications for radioactive iodine use. JAMA Otolaryngol Head Neck Surg 2013; 139: 479-482.
• 43 Nwatsock JF, Taieb D, Tessonnier L. et al. Radioiodine thyroid ablation in Graves’ hyperthyroidism: merits and pitfalls. World J Nucl Med 2012; 11: 7-11.
• 44 Perros P, Kendall-Taylor P, Neoh C. et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab 2005; 90: 5321-5323.
• 45 Reinhardt MJ, Joe A, von Mallek D. et al. Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of ^99mTc-pertechnetate thyroid uptake. Eur J Nucl Med 2002; 29: 480-485.
• 46 Reinhardt MJ, Brink I, Joe AY. et al. Radioiodine therapy in Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med 2002; 29: 1118-1124.
• 47 Reinhardt M, Kim B, Wissmeyer M. et al. Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of ^99mTc-pertechnetate: applicability to unifocal thyroid autonomy?. Eur J Nucl Med 2006; 33: 608-612.
• 48 Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab 2007; 92: 797-800.
• 49 Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 2003; 111: 745-749.
• 50 Rokni H, Sadeghi R, Moossavi Z. et al. Efficacy of different protocols of radioiodine therapy for treatment of toxic nodular goiter: systematic review and meta-analysis of the literature. Int J Endocrinol Metab 2014; 12: e14424.
• 51 Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid 2004; 14: 525-530.
• 52 Schicha H, Reiners C, Moser E, Schober O. Subclinical thyroid disease. Nuklearmedizin 2004; 43: 69-71.
• 53 Schmidt M, Gorbauch E, Dietlein M. et al. Incidence of post-radioiodine immunogenic hyperthyroidism / Graves’ disease in relation to a temporary increase in TSH-receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid 2006; 16: 281-288.
• 54 Selmer C, Olesen JB, Hansen ML. et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. Br Med J 2012; 345: e7895.
• 55 Selmer C, Olesen JB, Hansen ML. et al. Subclinical and ouvert thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014; 99: 2372-2382.
• 56 Shiber S, Stiebel-Kalish H, Shimon I. et al. Glucocorticoid regimens for prevention of Graves’ ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid 2014; 24: 1515-1523.
• 57 Silberstein EB, Alavi A, Balon HR. et al. The SNMMI practice guideline for therapy of thyroid disease with ¹³¹I 3.0. J Nucl Med 2012; 53: 1633-1651.
• 58 Silva MN, Rubió IG, Romão R. et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goiters. Clin Endocrinol (Oxf) 2004; 60: 300-308.
• 59 Stan MN, Durski JM, Brito JP. et al. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves’ ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid 2013; 23: 620-625.
• 60 Stokkel MPM, Handkiewicz Junak D, Lassmann M. et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 2010; 37: 2218-2228.
• 61 Strahlenschutz in der Medizin - Richtlinie zur Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung - StrlSchV). Gemeinsames Ministerialblatt. 2011 S. 867
• 62 Strahlenschutzkommission (SSK) des Bundesministeriums für Umwelt, Naturschutz und Reaktorsicherheit. Ambulante, fraktionierte Radioiodtherapie. Empfehlung der Strahlenschutzkommission vom 22./23. Februar 1996 Bundesanzeiger Nr. 132 (18.7.1996)
• 63 Strahlenschutzkommission (SSK) des Bundesministeriums für Umwelt, Naturschutz und Reaktorsicherheit. Strahlenschutzgrundsätze für die Radioiodtherapie. Empfehlung der Strahlenschutzkommission vom 5./6. Dezember 1996 Bundesanzeiger Nr. 68 (11.4.1997)
• 64 Strahlenschutzkommission (SSK) des Bundesministeriums für Umwelt, Naturschutz und Reaktorsicherheit. Nachsorge für Patienten nach Strahlenbehandlung. Empfehlung der Strahlenschutzkommission vom 11./12. Februar 1998 Bundesanzeiger Nr. 114 (6.8.1998)
• 65 Strahlenschutzverordnung. Textausgabe mit einer erläuternden Einführung von Hans-Michael Veith. 8. Aufl.. Köln: Bundesanzeiger-Verlag; 2010
• 66 Sung JY, Baek JH, Jung SL. et al. Radiofrequency ablation for autonomously functioning thyroid nodules: a multicenter study. Thyroid 2015; 25: 112-117.
• 67 Vannucchi G, Campi I, Covelli D. et al. Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 2009; 94: 3381-3386.
• 68 Vogt H, Wengenmair H, Kopp J. et al. Radioiodine therapy for combined disseminated and nodular thyroid autonomy. Nuklearmedizin 2006; 45: 101-104.
• 69 Walter MA, Crist-Crain M, Schindler C, Mueller-Brand J, Mueller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med 2006; 33: 730-737.
• 70 Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001; 86: 998-1005.
• 71 Willegaignon J, Sapienza MT, Buchpiguel CA. Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy - tuning the target for therapy planning. Clin Nucl Med 2013; 38: 231-236.
• 72 Zang S, Ponto KA, Kahaly G. Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011; 96: 320-332.